

*a2* 31. (Amended) A [pharmaceutically acceptable] formulation consisting essentially of at least one ecdysteroid and a pharmaceutically acceptable carrier.

*a3* 34. (Amended) A [formulation] kit according to claim 33 wherein said ecdysteroid is a naturally occurring ecdysone, an ecdysone analog or an ecdysone mimic.

Please add the following new claims:

*a4* 35. A method according to claim 4, wherein said member of the steroid/thyroid hormone superfamily of receptors is EcR, vitamin D<sub>3</sub> receptor, RAR $\alpha$ , RAR $\beta$ , RAR $\gamma$ , RXR $\alpha$ , RXR $\beta$ , RXR $\gamma$ , TR $\alpha$ , TR $\beta$ , or ER.

*a4* 36. A method according to claim 35, wherein the DNA-binding domain of the modified ecdysone receptor is characterized as having a P-box amino acid sequence that differs from the P-box amino acid sequence of the naturally occurring DNA-binding domain.

*a4* 37. A method according to claim 36, wherein said modified P-box amino acid sequence preferentially binds to a different hormone response element half-site than said naturally occurring P-box amino acid sequence.

*a4* 38. A method according to claim 37, wherein the DNA-binding domain of said modified ecdysone receptor is derived from EcR and the P-box amino acid sequence is GSCKV (SEQ ID NO:3).

*sub D5* 39. A method according to claim 13, wherein said first half-site is obtained from an ecdysone response element and said second half-site is obtained from a hormone response element selected from a glucocorticoid response element, a mineralocorticoid response element, a progesterone response element or an androgen response element.